08.28.25 -- Is Your Pharma Facility Ready For The Next Public Health Crisis?

Engineering controls designed to mitigate exposure and create separation between the operator and toxic material are available in many forms, all with their own unique advantages and risks.

Process intensification is here and transforming industries now. Discover how experts and early adopters are tackling challenges and unlocking new efficiencies through sustainable technologies.

See how evolving regulations and advanced therapies are reshaping Container Closure Integrity best practices with Dr. Derek Duncan and MSc. Josine Wilmer as they delve into real-world case studies.

Ensuring sterile drug production is vital for patient health and a key regulatory focus. Examine core principles and emerging trends in sterile manufacturing.

In biopharmaceutical manufacturing, seemingly minor components like seals can pose significant risks to product purity. Overlooking them can lead to contamination and costly delays.

Learn how a biodegradable polymer platform that is compatible with many substrates can enable several applications as a drug eluting carrier with a wide variety of APIs.

To derisk your manufacturing, work with an outsourcing partner that prioritizes the kilo lab as a space to develop a proven, robust, and reliable workflow from clinical to commercial scale.

Radiofrequency identification (RFID)-based unit-level tracking solutions for prefilled syringes are poised to help pharma manufacturers address key risks and costly bottlenecks related to the fill-finish process.

Uncover the ways to design and de-risk molecules, streamlining the path to GMP manufacturing and clinical trials, and case studies that provide insight into key activities.

Read about a collaboration that has yielded advanced modular cleanrooms, integrating cutting-edge building automation, critical monitoring, and data aggregation for manufacturing intelligence.

With a growing interest in developing new and improved bioconjugate drugs, find out how an “innovation through collaboration” approach can facilitate access to next-generation conjugation technologies.

Choosing the CDMO best suited to manufacture your rare disease therapy can be challenging. Ideally, a CDMO will prioritize your goals while working to ensure quality and regulatory success.